Itay & Beyond
Patient-derived lab grown brain tissue on a chip, to develop novel treatments for neurology and psyc
Company Overview
Snapshot
Founded in January 2021 by Nissim Perets, Itay & Beyond operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative platform for neuropsychiatric drug discovery. In February 2025, Itay & Beyond was highlighted for its use of AI analysis with brain-on-a-chip technology to predict drug efficacy for neuropsychiatric disorders.
Business overview
Itay & Beyond is a pioneering biotech startup focused on revolutionizing neuropsychiatric drug discovery. The company develops a platform utilizing patient-derived lab-grown brain tissue on a chip to create novel treatments for neurological and psychiatric conditions. It operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Digital Healthcare, with a focus on drug discovery and development for patients in the pharmaceutical and biotechnology industries.
Strategic signal
In February 2025, Itay & Beyond was featured for its innovative approach to neuropsychiatric drug discovery, utilizing AI analysis of a ‘brain-on-a-chip’ made from stem cells. This development signals a significant advancement in expediting drug testing and development, offering a more efficient and potentially more accurate method for predicting drug efficacy. For investors, this highlights the company's potential to address the urgent need for effective treatments in neuropsychiatry, leveraging cutting-edge technology to reduce R&D timelines and costs.
Log in to access full profile ›Company Intelligence Q&A
- What is Itay & Beyond's core technology?
- Itay & Beyond's core technology involves patient-derived, lab-grown brain tissue on a chip, which is used to develop novel treatments for neurology and psychiatry. This platform integrates AI analysis to predict drug efficacy.
- When was Itay & Beyond founded?
- Itay & Beyond was founded in January 2021.
- Who is a key founder of Itay & Beyond?
- Nissim Perets is a co-founder and CEO of Itay & Beyond.
- What was a significant development for Itay & Beyond in early 2025?
- In February 2025, Itay & Beyond was highlighted for its use of AI analysis with a 'brain-on-a-chip' made from stem cells to predict drug efficacy for neuropsychiatric disorders, aiming to expedite testing and development.
- What market need does Itay & Beyond address?
- Itay & Beyond addresses the urgent need for more effective treatments in neuropsychiatry by revolutionizing drug discovery through its advanced platform.